Green Tea Catechin Inhibits Fatty Acid Synthase without Stimulating Carnitine Palmitoyltransferase-1 or Inducing Weight Loss in Experimental Animals

TERESA PUIG1,2*, JOANA RELAT3*, PEDRO F. MARRERO3, DIEGO HARO3, JOAN BRUNET1 and RAMON COLOMER1,4

1Girona Biomedical Research Institute (IdIBGi) and Catalan Institute of Oncology, Dr. Josep Trueta University Hospital, Girona;
2Biochemistry and Molecular Biology, School of Biology, University of Girona, Girona;
3Biochemistry and Molecular Biology, School of Pharmacy, University of Barcelona, Barcelona;
4MD Anderson Cancer Center España, Madrid, Spain

Abstract. Background: The enzyme fatty acid synthase (FASN) is highly expressed in many human carcinomas and its inhibition is cytotoxic to human cancer cells. The use of FASN inhibitors has been limited until now by anorexia and weight loss, which is associated with the stimulation of fatty acid oxidation. Materials and Methods: The in vitro effect of (–)-epigallocatechin-3-gallate (EGCG) on fatty acid metabolism enzymes, on apoptosis and on cell signalling was evaluated. In vivo, the effect of EGCG on animal body weight was addressed. Results: EGCG inhibited FASN activity, induced apoptosis and caused a marked decrease of human epidermal growth factor receptor 2 (HER2), phosphatidylinositol 3-kinase (PI3K)/AKT and extracellular (signal)-regulated kinase (ERK) 1/2 proteins, in breast cancer cells. EGCG did not induce a stimulatory effect on CPT-1 activity in vitro (84% of control), or on animal body weight in vivo (99% of control). Conclusion: EGCG is a FASN inhibitor with anticancer activity which does not exhibit cross-activation of fatty acid oxidation and does not induce weight loss, suggesting its potential use as an anticancer drug.

The endogenous synthesis of fatty acids is usually minimal in animals because the diet supplies most of the fatty acids and, consequently, FASN is expressed at low or undetectable levels in non-malignant cells. In contrast, high levels of FASN have been reported in breast cancer and other human solid carcinomas (2-7). Treatment of cancer cells with some pharmacological inhibitors of FASN, such as the natural product cerulenin and its synthetic derivative C75 (8), are cytotoxic to breast cancer cells both in vitro (8-12) and in vivo (13). These FASN inhibitors provided the first evidence of anticancer activity, although they induced a profound decrease in food intake and body weight in rodents (14). C75 also activates different components of the carnitine palmitoyltransferase (CPT) system (15-17). The CPT system controls the entry of the long-chain fatty acids into the mitochondria, where they undergo β-oxidation. CPT-1 catalyses the first rate-limiting step in the CPT shuttle system and it is considered the most critical step in controlling fatty acid flux through its physiological inhibition by malonyl-CoA (15-18). Interestingly, CPT-1 stimulation appears important for the C75 anorexic effect, since selective CPT-1 pharmacological activation induces animal weight loss (19).

The biologically active anticancer components of green tea include polyphenolic catechins (20, 21). Several studies have indicated that epigallocatechin-3-gallate (EGCG) is the most abundant and biologically active catechin with respect to anticancer activity (22, 23). Different potential mechanisms contributing to the anticancer effects of tea catechin EGCG have been described, including blockade of methylation, inhibition of metalloproteinase and receptor tyrosine kinases (reviewed in 24). Recently, we and others have reported that EGCG induced apoptosis in cancer cells through the inhibition of FASN activity (12, 22, 25-29).

The aim of the present study was to search for a specific FASN inhibitor devoid of weight loss effects in vivo. For the...
first time to our knowledge, the effect of EGCG on CPT-1 activity in vitro and on body weight in vivo was evaluated. Additionally, evidence for the molecular signaling pathways involved in the cytotoxic effects was determined.

Materials and Methods

Cell lines and reagents. SK-BR3 was used as an optimal human breast cancer cell line due to its high constitutive FASN and human epidermal growth factor receptor 2 (HER2) expression and activity levels. The SK-BR3 cells were purchased from Eucellbank (Barcelona, Spain) and were cultured in McCoy’s 5A medium (Gibco, Berlin, Germany) containing 10% foetal bovine serum (FBS; Bio-Whittaker, Walkersville, MD, USA) 1% L-glutamine, 1% sodium pyruvate, 50 U/ml penicillin and 50 μg/ml streptomycin. EGCG and C75 were obtained from Sigma (St. Louis, MO, USA). The primary antibody for FASN immunoblotting was a mouse IgG1 FAS monoclonal antibody obtained from BD Biosciences Pharmingen (San Diego, CA, USA). Monoclonal anti-β-actin mouse antibody (clone AC-15) was obtained from Sigma. Anti-AKT, anti-phospho-AKTSer473 rabbit polyclonal antibodies and mouse monoclonal antibodies against p185HER2/neu (clone Ab-3) and phospho-p185HER2-neu were purchased from Cell Signaling Technology (Beverly, MD, USA). The assay of CPT-1 activity was conducted using palmitoyl-CoA lithium salt from Sigma, fatty acid-free BSA from Roche (Manheim, Germany), fatty acid synthase activity assay from Cell Signaling Technology (Beverly, MA, USA). CPT-1 activity was conducted by flow cytometry using the Annexin V-Alexa Fluor 488 (Alexa488) and propidium iodide (PI) staining Alexa Fluor 488 Apoptosis Detection Kit (Molecular Probes, USA). Treatment was conducted by flow cytometry using the Annexin V-fluorescein isothiocyanate (FITC) Apoptosis Detection Kit (BD Biosciences, USA). After the treatment, the animals were given free access to rodent chow for 24 h, at which time, the experiment finished and the animals were weighed again (Refed).

Measurement of carnitine palmitoyltransferase-1 (CPT-1) activity. CPT-1 activity was assayed by the forward exchange method using L-[3H]carnitine as previously described (12, 16). Briefly, the reaction mixture (total volume of 0.5 ml) consisted of the standard enzyme assay mixture with 200 μM C75 or EGCG, 0.2 mM L-[3H]carnitine (~5000 dpm/nmol), 80 μM palmitoyl-CoA, 20 mM HEPES (pH 7.0), 1% fatty acid-free albumin and 40-75 mM KCl, with or without malonyl-CoA (10 μM) as indicated. The reactions were initiated by the addition of isolated intact yeast mitochondria expressing recombinant CPTIA (16). The reaction was linear up to 4 min, and all the incubations were conducted at 30°C for 3 min. The reactions were stopped by the addition of 6% perchloric acid and the samples were then centrifuged at 2300 rpm for 5 min. The resulting pellet was suspended in water and the product [3H]palmitoylcarnitine was extracted with butanol at low pH. After centrifugation at 2500 rpm for 3 min, an aliquot of the butanol phase was transferred to a vial for radioactive counting.

Animal preparation for in vivo experiments. The animals were randomized into three groups of 5 animals each: control, C75-treated and EGCG-treated. All the experiments were conducted in accordance with guidelines on animal care and use established by the University of Barcelona School of Farmacia institutional animal care and scientific committee. The treatments were conducted as previously described by Cha et al. (30). Briefly, the mice were weighed (Fed) for 12 h during the dark cycle and weighed (Fasted) before treatment. Each group received a single intraperitoneal (i.p.) injection (0.5 ml) of FASN inhibitor (30 mg/kg) or vehicle alone (DMSO), dissolved in RPMI-1640 medium (Invitrogen, Life Technologies, Carslbad, CA, USA). After the i.p. injections, the animals were given free access to rodent chow for 24 h, at which time, the experiment finished and the animals were weighed again (Refed).
Statistical analysis. The data from the in vitro and in vivo results were analyzed by Student’s t-test or by one-way ANOVA using a Tukey test as a post-test. The data are reported as means±SD. All the observations were confirmed by at least three independent experiments. For all the tests, p<0.05 was considered statistically significant.

Results

Effect of EGCG on FASN and CPT-1 activity. Highlighted in Table I are the activity values of EGCG compared with C75 (included for comparative purposes) for key fatty acid metabolism enzymes. The inhibitor concentrations used were the IC\textsubscript{50} values of EGCG (150 μM) and C75 (30 μM) against SKBr-3 human breast cancer cells (data not shown). EGCG markedly reduced FASN activity in the SKBr-3 cells compared to the control (59±13%), comparable to the reduction obtained with C75 (43±4%). EGCG had no effect on the abundance of FASN protein levels, which was measured from the same treated samples by Western blot.

EGCG did not exert any significant effect on CPT-1 activity (84±16%, respect to control), in sharp contrast to C75 which, as previously reported, produced substantial activation of CPT-1 both in the absence (30.0%, in respect to control) and in the presence of inhibitory concentrations of malonyl-CoA (28.8%, in respect to control), a physiological inhibitor of CPT-1 (data not shown).

Effect of EGCG on apoptosis and oncogene HER2 activation. The treatment of the cancer cells with EGCG time-dependently increased the percentage of apoptotic cells, the induction of apoptosis was higher when the cells were treated with EGCG for 24 or 48 h (Figure 1A). The number of late apoptotic cells increased from 0.6% in non-EGCG treated cells to 11.2% with EGCG treatment for 24 h. Thus, the total percentage of apoptotic cells (UR + LR) increased from 1% in the control cells to 16.2% following the treatment with EGCG for 24 h (Figure 1A; panels C and D). Similarly, treatment of the SK-Br3 cells with EGCG for 48 h further increased the apoptosis. The number of late apoptotic cells increased from 0.7% in the non-treated cells to 21.2% in the cells treated with EGCG for 48 h. Thus, the total percentage of apoptotic cells (UR + LR) increased from 1.2% in the non-treated cells to 27.5% following the 48 h treatment with EGCG 150 μM (Figure 1A; panels E and F). Apoptosis and the induction of caspase activity was also confirmed by Western blot analysis showing cleavage of poly(ADP-ribose) polymerase (PARP) after EGCG treatment (data not shown).

Figure 1B shows that EGCG dramatically reduced HER2 phosphorylation (p-HER2) within 6 h after treatment; reduction was already marked as soon as 2 h after EGCG treatment (data not shown) and was completed by 6 h after treatment. During this period, there was no significant change in the total level of HER2, as assessed by Western blotting analysis (Figure 1B) or by HER2-specific ELISA (data not shown). Similarly, EGCG markedly reduced the expression levels of both, p-AKT and p-ERK1/2 proteins within 12 h after exposure. During this period, there was no significant change in the total level of the respective proteins (Figure 1B). Together, these changes were not due to a reduction in FASN protein levels, as confirmed by immunoblot analysis, using the same treated samples in which FASN activity was measured (Figure 1B).

Weight loss in vivo. The mice treated with a single i.p. dose of C75 (30 mg/kg) showed a body weight loss of 20.1% compared to the control group, as expected (Figure 2). Remarkably, under the same conditions, the EGCG-treated mice (30 mg/kg) did not show any significant weight loss (0.7% of control group). For further confirmation, mice treated with a single i.p. dose of EGCG (150 mg/kg, 5-fold the C75 dose) did not show any significant weight loss and appeared healthy after treatment (data not shown). This was consistent with the in vitro results of CPT-1 activity shown in Table I.

Discussion

FASN has emerged as a promising drug target for anticancer drug development (8, 9, 11, 12, 31, 32) although specific inhibitors have not been found. Previous independent in vitro studies showed that pharmacological blockade of FASN activity using EGCG inhibited the proliferation of human cancer cells in vitro (12, 24-26). Additionally, we reported that EGCG-induced cytotoxicity toward three human metastatic breast cancer cell lines (MDA-MB-231, MCF-7 and SK-Br3) expressing different FASN protein levels was directly dependent on the cell FASN level; EGCG potently decreased FASN activity and its ability to inhibit FASN was consistent with the in vitro results of CPT-1 activity shown in Table I.

Table I. Effect of green tea catechin on fatty acid metabolism pathways

<table>
<thead>
<tr>
<th>Compound</th>
<th>FASN inhibition(^a)</th>
<th>CPT-1 stimulation(^b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGCG</td>
<td>58.9±12.8(^d)</td>
<td>84±16</td>
</tr>
<tr>
<td>C75</td>
<td>43.3±4.1(^d)</td>
<td>129±18(^*)</td>
</tr>
<tr>
<td>Vehicle (control)</td>
<td>N.E.</td>
<td>N.E.</td>
</tr>
</tbody>
</table>

FASN: Fatty acid synthase; CPT-1: carnitine palmitoyltransferase-1; N.E.: No effect; \(^a\)Data are % nmol of NADPH oxidized/min × mg protein of control cells; \(^b\)Data are % mU/mg × min of control cells; Data are expressed as mean±SD (N=3). \(^*p<0.05, \)^\({ }^p<0.01.\n
3673
cell contact and formation of cellular aggregates) to those observed after siRNA-mediated FASN inhibition (12), implying the reliance of cancer cell survival on FASN expression and activity.

Prior in vitro studies from our laboratory with human breast cancer cells using classic FASN inhibitors (cerulenin, C75) showed that HER2/neu overexpression and its downstream signaling pathways including phosphatidylinositol 3-kinase (PI3K)/AKT and mitogen-activated protein kinase (MAPK) were linked to FASN-induced cytotoxicity (12, 31, 33) through steroid regulatory element binding protein 1c (SREBP-1c). FASN blockage using EGCG induced apoptosis and caused a marked decrease in the levels of activated HER2, ERK1/2 and AKT proteins. The present data with EGCG were thus in accordance with those supporting a model in which MAPK and PI3K/AKT activation up-regulates FASN expression in breast, colon, ovarian and prostate cancer cells (34, 35). Future molecular studies of FASN inhibition in cancer cells are likely to explore pathways that modulate apoptosis and continue to search for the biochemical link between FASN inhibition and cancer cell death.

Whereas initial studies with C75, a synthetic FASN inhibitor, showed significant antitumor activity against human xenografts, its therapeutic use was limited by dramatic weight loss (14, 36, 37). C75 is also a stimulator of fatty acid oxidation via activation of CPT-1 (12, 15-17), a paradoxical effect considering that FASN inhibition increases levels of malonyl-CoA, the physiological CPT-1 inhibitor (Figure 3). Recently, it has been postulated that C75-induced weight loss occurred predominantly from its capacity to stimulate CPT-1 and accelerate fatty acid β-oxidation, rather than from a FASN inhibition-dependent mechanism (30). Regarding EGCG, although the effects of extracts of green tea leaves on fatty acid oxidation have been previously investigated (38, 39), this was the first study to analyze the effect of purified EGCG both on fatty acid oxidation regulatory enzyme (CPT-1) in vitro and on body weight loss in vivo. EGCG did not stimulate CPT-1 activity (=84%), and in the animal studies, EGCG did not induce any appreciable weight loss after a
single i.p. 30 mg/kg or 150 mg/kg dose, compared with the profound weight loss induced by C75 treatment (20.1% of control mice). The present in vivo results with C75 were similar to those reported by Thupari et al. (15) in which 16% loss of body mass was observed in mice treated with C75 at 20 mg/kg i.p. within the first two days of C75 treatment.

In summary, the present results confirmed that EGCG is a potent and specific FASN inhibitor with in vitro anticancer activity. Interestingly, the present findings are the first to indicate that EGCG does not exhibit cross-activation of fatty acid oxidation and, most importantly, does not induce animal weight loss, suggesting its potential use as a novel target-directed anticancer drug for future in vivo studies, administered alone or in a combination regimen.

Acknowledgements

Financial support was provided by grants from the Susan G. Komen Breast Cancer Foundation (PDF-0304073; R. Colomer), the Spanish Ministerio de Educación y Ciencia, MEC (JCI-2005-001616001-Programa Juan de la Cierva; T. Puig and BFU2007-67322/BMC; P. F. Marrero), the Spanish Society of Medical Oncology (SEOM; R. Colomer and T. Puig) and the Instituto de Salud Carlos III (FIS PI04/1417; R. Colomer, RD06-0020-0028; R. Colomer and ISCIII-RETIC RD06; D. Haro).

References


Received May 16, 2008
Revised July 16, 2008
Accepted August 14, 2008